Andrographis paniculata	Placebo	Relapse rate	1290	1463	No statistically significant differences were observed for relapse rate, EDSS or inflammatory parameters, with a trend in reducing new lesions among the A. paniculata group.
Andrographis paniculata	Placebo	Inflammatory parameters	1290	1463	No statistically significant differences were observed for relapse rate, EDSS or inflammatory parameters, with a trend in reducing new lesions among the A. paniculata group.
Andrographis paniculata	Placebo	Inflammatory parameters	1290	1394	No statistically significant differences were observed for relapse rate, EDSS or inflammatory parameters
Andrographis paniculata	Placebo	Expanded Disability Status Scale	-1	-1	The EDSS score during the total period of treatment was similar for the A. paniculata and the placebo groups, and no significant differences were observed
Andrographis paniculata	Placebo	Expanded Disability Status Scale	1290	1463	No statistically significant differences were observed for relapse rate, EDSS or inflammatory parameters, with a trend in reducing new lesions among the A. paniculata group.
Andrographis paniculata	Placebo	Fatigue Severity Scores	1131	1288	Patients treated with A. paniculata showed a significant reduction in their FSS score as compared to the placebo, equivalent to a 44 % reduction at 12 months
Andrographis paniculata	Placebo	Relapse rate	1290	1362	No statistically significant differences were observed for relapse rate,
